Results

Total Results: 1,643 records

Showing results for "factor".

61. Evidence-based Practice Center Systematic Review Protocol (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/juvenile-arthritis-dmards_research-protocol.pdf
    March 09, 2010 - : affects five or more joints during the first 6 months of disease; is subclassified as rheumatoid factor-negative … and rheumatoid factor-positive disease, the latter of which may be associated with more destructive … nephrotoxicity; hepatotoxicity D-Penicillamine Depen Cuprimine Unknown (may lower IgM rheumatoid factor … sensitivity analyses include: study quality, including the quality of the measurement of exposure to the factor … Settings RCTs Randomized Controlled Trials TEP Technical Expert Panel TNF Tumor Necrosis Factor

62. Vte-Prophyalaxis Executive (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/vte-prophyalaxis_executive.pdf
    May 01, 2013 - Rivaroxaban was included; it is an oral factor Xa inhibitor that the FDA approved in July 2011 for … direct thrombin inhibitors) • IVC filters • Mechanical devices • Pharmacologic (UFH LMWHs, factor … Xa inhibitors, direct thrombin inhibitors) • Pharmacologic (UFH, LMWHs, factor Xa inhibitors, … direct thrombin inhibitors) • Mechanical devices IVC filters • Pharmacologic (UFH LMWHs, factor … studies, studies that used active controls, and uncontrolled studies • Low-dose UFH, LMWHs, factor

63. Data Points #15: Prognostic factor testing among older women with ductal carcinoma in situ and early invasive breast cancer | Effective Health Care (EHC) Program
    effectivehealthcare.ahrq.gov/products/dcis-prognostic-tests/research

64. PULMONARY with "Discussions" in Exec Summary (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pulmonary-horizon-scan-high-impact-1412.pdf
    October 01, 2015 - tyrosine kinase inhibitor that targets the intracellular signaling of multiple proangiogenic growth factor … receptors purportedly involved in the pathogenesis of IPF, including vascular endothelial growth factor … receptor 2 (VEGFR2), fibroblast growth factor receptor (FGFR), and platelet-derived growth factor … receptor kinase activity of vascular endothelial growth factor receptor 2 (VEGFR2), fibroblast growth … factor receptor (FGFR), and platelet-derived growth factor receptor (PDGFR).

65. Methods Guide for Medical Test Reviews Chapter 6 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/methods-guidance-tests-applicability_methods.pdf
    July 01, 2012 - Decisions should be based on whether there is evidence that a particular contextual factor is expected … assessing the accuracy of cardiac MRI for detecting atherosclerosis, slice thickness is a relevant factor … Preventive Care Over Time Routine use of a medical test as a screening test might be considered an indirect factor … In some cases, failing to consider a particular factor may have been an oversight; in retrospect, the … importance of that factor on the applicability of test results may be physiologically sensible and

66. Evidence-based Practice Center Systematic Review Protocol (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/pressure-ulcer-prevention_research-protocol.pdf
    January 10, 2012 - and Specificity"/ or "Reproducibility of Results"/ or "Severity of Illness Index"/ or (risk adj2 (factor … Sensitivity and Specificity"/ 12 "Reproducibility of Results"/ 13 or/6-12 14 (risk adj2 (factor … Sensitivity and Specificity"/ 12 "Reproducibility of Results"/ 13 or/6-12 14 (risk adj2 (factor … Results") S13 (MH "ROC Curve") S14 S7 or S8 or S9 or S10 or S11 or S12 or S13 S15 "risk factor … Sensitivity and Specificity"/ 12 "Reproducibility of Results"/ 13 or/6-12 14 (risk adj2 (factor

67. #06 Developmental Delays ADHD, and Autism (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/developmental-delays-horizon-scan-high-impact-1312.pdf
    December 01, 2013 - Oxytocin factor - 30 ml nasal spray. [internet]. Amazon.com, Inc. … Available: http://www.amazon.com/Oxytocin- Factor-30-Nasal-Spray/dp/B007K8LTD2. 30. … Oxytocin factor. [internet]. ABC Nutriceuticals [accessed 2013 Nov 21]. [2 p]. … startswith=oxytocin&x=0&y=0 http://www.fda.gov/ http://www.amazon.com/Oxytocin-Factor-30-Nasal-Spray/ … dp/B007K8LTD2 http://www.amazon.com/Oxytocin-Factor-30-Nasal-Spray/dp/B007K8LTD2 http://tryoxytoday.com

68. Atrial-Fibrillation-Ablation Surveillance (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/atrial-fibrillation-ablation_surveillance.pdf
    May 16, 2013 - recurrence rates, three studies showed that gender was either a significant predictor or protective factor … vs. no AF recurrence Female gender: HR=0.092, 95% CI: 0.022, 0.386 (female gender as a protective factor … AF recurrence) HR=0.58, 95% CI: 0.36, 0.94 [MVA] (absence of coronary disease as a protective factor … No AF termination 38(5) vs. 44(8); smaller LA diameter [mm] as a protective factor against AF, MVA … against AF recurrence, MVA) OR=0.051, 95% CI: 0.008, 0.338 (PAF as a protective factor against

69. Venous Thromboembolism Prophylaxis in Major Orthopedic Surgery: Systematic Review Update (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/thromboembolism-update-executive-170622.pdf
    June 01, 2017 - molecular weight heparin (LMWH), vitamin K antagonists (VKA), antithrombin III-mediated selective factor … Xa inhibitors, direct factor Xa inhibitors (FXaI), bivalent and univalent direct thrombin inhibitors … Mechanical prophylaxis aims to minimize stasis, the principal putative factor resulting in venous thrombosis … the searches from the 2012 VTE report and added additional 4 terms for new treatments (e.g., factor … VIII inhibitors (FEI), factor Xa inhibitors (FXaI), factor XI inhibitors (FXIi), direct thrombin inhibitors

70. Venous Thromboembolism Prophylaxis in Major Orthopedic Surgery: Systematic Review Update (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/thromboembolism-update-executive-170622.pdf
    June 01, 2017 - molecular weight heparin (LMWH), vitamin K antagonists (VKA), antithrombin III-mediated selective factor … Xa inhibitors, direct factor Xa inhibitors (FXaI), bivalent and univalent direct thrombin inhibitors … Mechanical prophylaxis aims to minimize stasis, the principal putative factor resulting in venous thrombosis … the searches from the 2012 VTE report and added additional 4 terms for new treatments (e.g., factor … VIII inhibitors (FEI), factor Xa inhibitors (FXaI), factor XI inhibitors (FXIi), direct thrombin inhibitors

71. Slide 1
    effectivehealthcare.ahrq.gov/sites/default/files/estimation-and-reporting_chapter-3.pptx
    January 01, 2013 - disease, the effect of exposure on outcome (treatment effect) differs according to the level of the other factor … that the effect of exposure on outcome (treatment effect) differs according to the level of the other factor … treatment effect may be required even when the variable that modifies treatment effect is not a risk factor

72. PowerPoint Presentation (ppt file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/medical-test-reviews-applicability.ppt
    June 01, 2012 - Example: Slice thickness is a relevant factor for assessing the applicability/accuracy of cardiac magnetic … Principle 1: Identify Important Contextual Factors (2 of 10) The first contextual factor is spectrum … Principle 1: Identify Important Contextual Factors (3 of 10) The second contextual factor concerns where … Principle 1: Identify Important Contextual Factors (4 of 10) The third contextual factor concerns the … Principle 1: Identify Important Contextual Factors (9 of 10) The sixth and final contextual factor to

73. PowerPoint Presentation (ppt file)
    effectivehealthcare.ahrq.gov/sites/default/files/medical-test-reviews-applicability.ppt
    June 01, 2012 - Example: Slice thickness is a relevant factor for assessing the applicability/accuracy of cardiac magnetic … Principle 1: Identify Important Contextual Factors (2 of 10) The first contextual factor is spectrum … Principle 1: Identify Important Contextual Factors (3 of 10) The second contextual factor concerns where … Principle 1: Identify Important Contextual Factors (4 of 10) The third contextual factor concerns the … Principle 1: Identify Important Contextual Factors (9 of 10) The sixth and final contextual factor to

74. Evidence-based Practice Center Systematic Review Protocol (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/tinnitus_research-protocol.pdf
    February 22, 2012 - traditional Chinese medicinal treatment used to increase blood flow, inhibit the platelet-activating factor … basis of the design or analysis a) study controls for _______________ (Select the most important factor … control for a second important factor.) … ) * b) study controls for any additional factor * (This criteria could be modified to indicate specific … - Appropriate methods are used if imputation is used for missing prognostic factor ☐

75. Cystic-Fibrosis-Hgh Surveillance (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cystic-fibrosis-hgh_surveillance.pdf
    August 01, 2012 - safety concerns • Evaluation of the safety and efficacy of recombinant human Insulin-like Growth Factor-I … However, we also accepted for review studies of insulin-like growth factor I for the treatment of cystic … [IGF-I] increases over 100 ng/ml or insulin –like growth factor binding protein-3 [(IGFBP-3] decreases … I; IGFBP insulin-like growth factor binding protein; LBM lean body mass; MHRA Medicines and Healthcare … [IGF-I] increases over 100 ng/ml or insulin –like growth factor binding protein-3 [(IGFBP-3] decreases

76. Methods Guide for Medical Test Reviews - Editorial (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/methods-guide-editorial_methods.pdf
    July 01, 2012 - fields of general internal medicine, family practice, nursing, and mental health, the average impact factor … for systematic reviews was 26.5.1 In contrast, the mean impact factor for the top 40 general medical

77. Layout 1 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/ace-inhibitor-arb-2007_executive.pdf
    January 01, 2007 - In addition to being the number one attributable risk factor for death throughout the world, hypertension … Risk factor reduction and other Moderate (lipid There were no consistent differential effects of ACEIs

78. VTE Surveillance Assessment_49_low_SPI (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/blood-clots-hip-knee-surgery_surveillance.pdf
    December 01, 2012 - Classes include oral antiplatelet agents, injectable LMWHs, injectable UFH, injectable or oral factor … As such, it is likely inferior to factor Xa inhibitors in the balance of benefits and harms as well … UFH vs. factor Xa inhibitors vs. … A dose- ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous … UFH vs. factor Xa inhibitors vs.

79. Effective Health Care (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/TND_0398_06-17-2008.pdf
    January 01, 2008 - )  Anemia in patients with end-stage renal disease (ESRD) is a risk factor for increased mortality

80. #06 Developmental Delays ADHD, and Autism (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/developmental-delays-horizon-scan-high-impact-1406.pdf
    June 01, 2014 - Oxytocin factor - 30 ml nasal spray. [internet]. Amazon.com, Inc. … Available: http://www.amazon.com/Oxytocin- Factor-30-Nasal-Spray/dp/B007K8LTD2. 42. … Oxytocin factor. [internet]. ABC Nutriceuticals [accessed 2013 Nov 21]. [2 p]. … startswith=oxytocin&x=0&y=0 http://www.fda.gov/ http://www.amazon.com/Oxytocin-Factor-30-Nasal-Spray/ … dp/B007K8LTD2 http://www.amazon.com/Oxytocin-Factor-30-Nasal-Spray/dp/B007K8LTD2 http://tryoxytoday.com